Expanded Access Policy

Clear Scientific is committed to developing promising new therapies that address the unmet medical needs of patients suffering from life-threatening and debilitating conditions caused by an excess of harmful substances in the body. 

  

We currently have clinical-stage investigational medicines in our product pipeline for the treatment of acute methamphetamine and fentanyl intoxication. Our goal is to provide access to our medicines rapidly, effectively, and in a manner that is most beneficial to the relevant patient population. We believe enrollment in our ongoing clinical trials is the safest and most effective way of achieving this goal. 

 

We do recognize that some patients will not be eligible for our clinical trials and may wish to access our therapeutics through compassionate use, “right-to-try”, Expanded Access, and other pre-approval programs. However, after careful consideration, Clear Scientific has determined we are unable to support a program to offer Expanded Access use of our investigational medicines at this time.  

 

We encourage all patients and physicians who are interested in accessing our investigational medicines to participate in our clinical trials. 

 

Clear Scientific may revise this expanded access policy at any time.  

 

Additionally, the posting of this policy by Clear Scientific does not serve as a guarantee of access to any specific investigational new drug by any individual patient. 

 

If you have any questions, please reach out to us at info@clearsci.com. You can find further contact details on the Contact Us page of our website. 

We may change this policy at any time.  Please check back periodically for updates on Expanded Access Policy clinical trials.